DNA vs. RXRX, BEAM, SANA, FUSN, APGE, INBX, CGON, KYMR, VCEL, and DNLI
Should you be buying Ginkgo Bioworks stock or one of its competitors? The main competitors of Ginkgo Bioworks include Recursion Pharmaceuticals (RXRX), Beam Therapeutics (BEAM), Sana Biotechnology (SANA), Fusion Pharmaceuticals (FUSN), Apogee Therapeutics (APGE), Inhibrx (INBX), CG Oncology (CGON), Kymera Therapeutics (KYMR), Vericel (VCEL), and Denali Therapeutics (DNLI). These companies are all part of the "biological products, except diagnostic" industry.
Recursion Pharmaceuticals (NASDAQ:RXRX) and Ginkgo Bioworks (NYSE:DNA) are both mid-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, community ranking, earnings, institutional ownership, media sentiment and dividends.
Ginkgo Bioworks has a net margin of -355.08% compared to Ginkgo Bioworks' net margin of -735.99%. Recursion Pharmaceuticals' return on equity of -48.23% beat Ginkgo Bioworks' return on equity.
Recursion Pharmaceuticals has a beta of 0.85, suggesting that its share price is 15% less volatile than the S&P 500. Comparatively, Ginkgo Bioworks has a beta of 1.42, suggesting that its share price is 42% more volatile than the S&P 500.
Recursion Pharmaceuticals has higher earnings, but lower revenue than Ginkgo Bioworks. Recursion Pharmaceuticals is trading at a lower price-to-earnings ratio than Ginkgo Bioworks, indicating that it is currently the more affordable of the two stocks.
Ginkgo Bioworks received 2 more outperform votes than Recursion Pharmaceuticals when rated by MarketBeat users. However, 51.22% of users gave Recursion Pharmaceuticals an outperform vote while only 50.00% of users gave Ginkgo Bioworks an outperform vote.
Recursion Pharmaceuticals presently has a consensus price target of $12.75, suggesting a potential upside of 48.26%. Ginkgo Bioworks has a consensus price target of $2.20, suggesting a potential upside of 189.13%. Given Recursion Pharmaceuticals' higher probable upside, analysts plainly believe Ginkgo Bioworks is more favorable than Recursion Pharmaceuticals.
In the previous week, Ginkgo Bioworks had 5 more articles in the media than Recursion Pharmaceuticals. MarketBeat recorded 25 mentions for Ginkgo Bioworks and 20 mentions for Recursion Pharmaceuticals. Ginkgo Bioworks' average media sentiment score of 0.52 beat Recursion Pharmaceuticals' score of 0.08 indicating that Recursion Pharmaceuticals is being referred to more favorably in the media.
89.1% of Recursion Pharmaceuticals shares are held by institutional investors. Comparatively, 78.6% of Ginkgo Bioworks shares are held by institutional investors. 15.8% of Recursion Pharmaceuticals shares are held by insiders. Comparatively, 15.1% of Ginkgo Bioworks shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Summary
Ginkgo Bioworks beats Recursion Pharmaceuticals on 10 of the 18 factors compared between the two stocks.
Get Ginkgo Bioworks News Delivered to You Automatically
Sign up to receive the latest news and ratings for DNA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Ginkgo Bioworks Competitors List
Related Companies and Tools
